Close Menu

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) has issued a new draft report recommending against the histology-independent use of larotrectinib (Bayer's Vitrakvi) for advanced adult and pediatric cancer patients treated through the National Health Service (NHS), even for rare cancer types or when no other satisfactory treatment options exist.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.